GILD Gilead Sciences
Nasdaq 100 CompaniesS&P 500 Companies
Healthcare · Biological Products, (No Diagnostic Substances)
Gilead Sciences (GILD) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $153.5 billion. Shares last traded at $123.63, 21.4% below their 52-week high. Over the past year the stock is up 12.4%. GILD trades at a price-to-earnings ratio of 18.04, below the Biological Products, (No Diagnostic Substances) median of 22.74. Net profit margin is 28.9%, above the peer median of 6.3%. Revenue grew 2.4% year over year. The shares yield 3.9% in dividends.
Performance
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
Financials
Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q1 2026 | $1.61 | 2026-05-07 |
| FY 2025 | $6.78 | 2026-02-24 |
| Q3 2025 | $5.04 | 2025-11-07 |
| Q2 2025 | $2.61 | 2025-08-07 |
| Q1 2026 | $1.04 | 2026-05-07 |
| FY 2025 | $0.38 | 2026-02-24 |
Biological Products, (No Diagnostic Substances) peers
GILD vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap.
| AMGN | Amgen | $182.1B | 23.62 | 4.96 | 21.0% | -1.27% |
| GILD | Gilead Sciences | $153.5B | 18.04 | 5.21 | 28.9% | -1.46% |
| RVMD | Revolution Medicines, Inc. | $34.6B | -30.62 | — | — | +3.14% |
| BIIB | Biogen | $29.0B | 22.44 | 2.93 | 13.1% | -1.15% |
| MRNA | Moderna | $25.4B | -8.99 | — | — | +3.22% |
| NBIX | Neurocrine Biosciences Inc | $15.9B | 33.24 | 5.56 | 16.7% | -0.48% |
| EXEL | Exelixis, Inc. | $13.1B | 16.68 | 5.62 | 33.7% | -1.04% |
| KRYS | Krystal Biotech, Inc. | $10.2B | 50.02 | 26.33 | 52.6% | +1.68% |
| TECH | Bio-Techne | $9.1B | 123.61 | 7.44 | 6.0% | +5.36% |
| HALO | Halozyme Therapeutics, Inc. | $8.1B | 25.67 | 5.82 | 22.7% | -0.03% |
| IBRX | Immunitybio, Inc. | $7.7B | -21.87 | — | — | +5.01% |
| RGEN | Repligen Corp | $7.4B | 152.27 | 10.08 | 6.6% | -1.20% |
| KYMR | Kymera Therapeutics, Inc. | $7.4B | 23.88 | — | — | +0.44% |
| PCVX | Vaxcyte, Inc. | $7.4B | -9688.00 | — | — | +1.57% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.